Sharps Technology Inc

Sharps Technology, Inc. is a pre-revenue medical device company. It designs and patents various safety syringes and is seeking commercialization by manufacturing and distributing its products. The company was founded by Alan Blackman and Barry B. Berler in 2017 and is headquartered in Melville, NY.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sharps Technology, Inc. is a medical device and pharmaceutical packaging company, which engages in the development and manufacturing of innovative drug delivery systems. It also focuses on low waste, and ultra-low waste syringe technologies that incorporate both passive and active safety features. The company was founded by Alan R. Blackman and Barry B. Berler on December 16, 2017 and is headquartered in Melville, NY.

NEW YORK, NY / ACCESSWIRE / September 29, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.6 Million Registered Direct & Private Placement Priced at the Market Under Nasdaq Rules for Sharps Technology, Inc. (NASDAQ:STSS). About Sharps Technology, Inc. Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry.

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.6 Million Registered Direct & Private Placement Priced at the Market Under Nasdaq Rules for Sharps Technology, Inc. (NASDAQ: STSS)

NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced registered direct offering and concurrent private placement with institutional investors.

Sharps Technology Announces Closing of $5.6 Million Registered Direct and Private Placement

American Resources Corp

Reviva Pharmaceuticals

ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 30, at 7 p.m. Eastern Time (ET).

Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

Sharps Technology Issues Letter to Shareholders Covering the Announced Asset Purchase Agreement to Acquire InjectEZ Prefillable Syringe Manufacturing Facil

Sharps Technology Issues Letter to Shareholders Covering the Announced Asset Purchase Agreement to Acquire InjectEZ Prefillable Syringe Manufacturing Facility and the Associated $400 Million 10-Year Purchase Agreement with Nephron Pharmaceuticals

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) --  Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into a definitive agreement with institutional investors for the purchase and sale of 4,418,521 shares of common stock and pre-funded warrants to acquire common stock in a registered direct offering. The purchase price of each share is $0.64. The purchase price for the pre-funded warrants is identical to the purchase price for shares, less the exercise price of $0.001 per share.

UPDATE - Sharps Technology Announces $5.6 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into a definitive agreement with institutional investors for the purchase and sale of 4,418,521 shares of common stock and pre-funded warrants to acquire common stock in a registered direct offering.

Sharps Technology Announces $5.6 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules

$50 Million acquisition of InjectEZ strengthens manufacturing capacity and establishes Sharps' leading position in the specialized copolymer prefillable syringe system industry Signed term sheet providing for up to $75 Million in debt financing to be used for the acquisition Nephron commits to minimum orders of over $400 Million over 10 years; $30 Million in revenue the first year and subsequent minimum orders totaling over $45 Million in annual revenue through December of 2033 NEW YORK and WEST COLUMBIA, S.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, and Nephron Pharmaceuticals Corporation, (“Nephron”) a privately owned U.S. leader in contract manufacturing and 503B outsourcing, announce the signing of an Asset Purchase Agreement (APA) to acquire Nephron's InjectEZ specialty syringe manufacturing facility.

Sharps Technology Signs Asset Purchase Agreement to Acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility and a 10-Year Purchase Agreement for Over $400 Million from Nephron Pharmaceuticals

Bullfrog AI Holdings Inc

Lantern Pharma

Zomedica

New podcast series shines a spotlight on undervalued small-cap and microcap stocks ORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money." Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players.

RedChip Launches 'Small Stocks, Big Money' Podcast

Key appointment with demonstrated experience in leading sales and marketing operations to oversee commercial initiatives as the Company launches its specialty smart safety syringe products to the market

Sharps Technology Appoints Industry Sales and Manufacturing Leader Ben Scheu as Senior Director of Sales

Company advances commercialization of Securegard smart safety syringe product line through qualification programs with a major medical device company

Sharps Technology Provides Update on Commercialization Activities and is Highlighted in Med Tech Outlook Feature Article

ORLANDO, FL / ACCESSWIRE / May 19, 2023 / RedChip Companies will air new interviews with Sharps Technology, Inc. (NASDAQ:STSS; STSSW) and BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) on The RedChip Money Report® on Bloomberg TV, this Saturday, May 20, at 7 p.m. Eastern Time (ET).

Sharps Technology, Inc. and BullFrog AI Holdings, Inc. Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / April 5, 2023 / RedChip Companies will air new interviews with BullFrog AI (NASDAQ:BFRG) and Sharps Technology (NASDAQ:STSS) on The RedChip Money Report® on Bloomberg TV, this Saturday, April 8, at 7 p.m. Eastern Time (ET).

BullFrog AI and Sharps Technology Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

Specialty plastics Engineer with 15+ years' experience in operations management strengthens Sharps senior leadership team and supports technical innovation and manufacturing through the Company's ongoing transition to commercial operations Specialty plastics Engineer with 15+ years' experience in operations management strengthens Sharps senior leadership team and supports technical innovation and manufacturing through the Company's ongoing transition to commercial operations

Sharps Technology Appoints Justin Page as Vice President of Technical Operations

NEW YORK, NY / ACCESSWIRE / February 6, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.8 Million Private Placement for Sharps Technology, Inc. (NASDAQ:STSS). About Sharps Technology, Inc. Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems.

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.8 Million Private Placement for Sharps Technology, Inc. (NASDAQ:STSS)

NEW YORK, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, today announced that it closed its previously announced private placement pursuant to a securities purchase agreement with institutional investors on February 3, 2023. The aggregate gross proceeds of the private placement were approximately $3.8 million priced at the market under Nasdaq rules. Proceeds will help support the manufacturing of pre-filled specialty syringe systems through its partnership with Nephron Pharmaceuticals.

Sharps Technology Announces Closing of $3.8 Million Private Placement Priced At-the-Market

Proceeds to support the manufacturing of pre-filled specialty syringe systems through its partnership with Nephron Pharmaceuticals Proceeds to support the manufacturing of pre-filled specialty syringe systems through its partnership with Nephron Pharmaceuticals

Sharps Technology Announces Pricing of $3.8 Million Private Placement Priced at the Market

NEW YORK, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces they have commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary. The plant has been producing products and will begin shipments to support the distribution and sales agreement with Nephron Pharmaceuticals by the end of the year, and customer agreements in Europe in early 2023. The production of these specialty syringe products will ramp up over the next several months to increase supply.

Sharps Technology Begins Manufacturing at its Hungary Facility for the Company's Innovative Syringe Products

NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the signing of a distribution agreement with partner Nephron Pharmaceuticals. This is a strategic first step in building the larger partnership between the two companies and is in support of their recently announced collaboration.

Sharps Technology and Nephron Pharmaceuticals Sign Distribution Agreement for its Innovative Syringe Products

Bluejay Diagnostics

Biosig Technologies Inc

The Dow Jones closed higher by more than 400 points on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Bluejay Diagnostics (NASDAQ:BJDX), BioSig Technologies (NASDAQ:BSGM) – Sharps Technology And 2 Other Stocks Under $2 Insiders Are Aggressively Buying

FDA/CE-Mark facility to produce our full range of world-class specialty safety syringes FDA/CE-Mark facility to produce our full range of world-class specialty safety syringes

Sharps Technology Completes Acquisition of Safegard Medical Syringe Manufacturing Facility

NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), is an innovative medical device company offering patented, best-in-class, single use smart safety syringe products, published a letter to shareholders. from Robert Hayes, CEO and from Alan Blackman and Soren Christiansen on behalf of the board.

Sharps Technology Announces Letter to Shareholders

Ambev

Mountain Crest Acquisition Corp II

Check these tips out for trading penny stocks in 2022 The post What You Need to Know About Buying Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What You Need to Know About Buying Penny Stocks in 2022

Medical syringe company Sharps Technology is on the move today. Here's what investors need to know about STSS stock.

Why Is Sharps Technology (STSS) Stock in the Spotlight Today?

NEW YORK, NY / ACCESSWIRE / April 19, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a ~$16 Million Initial Public Offering for Sharps Technology, Inc. (NASDAQ:STSS). About Sharps Technology, Inc. Sharps Technology, Inc. is a medical device company addressing global issues while engineering a safer future for healthcare providers and people everywhere through compassionate innovation.

Aegis Capital Corp. Acted as Sole Bookrunner on a ~$16 Million Initial Public Offering for Sharps Technology, Inc. (NASDAQ: STSS)

NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device company offering patented, best-in-class, single use smart safety syringe products, today announced the closing of its initial public offering of 3,750,000 units at a public offering price of $4.25 per unit. Each unit consisted of a share of common stock and two warrants to purchase one share of common stock each with an exercise price of $4.25. The underwriter partially exercised its over-allotment option with respect to 1,125,000 warrants. At the closing, the Company issued an aggregate of 3,750,000 shares of common stock and 8,625,000 warrants. Gross proceeds for the offering were approximately $16 million, before deducting underwriting discounts and commissions and estimated offering expenses.

News for Sharps Technology Inc Stock (STSS)